Here are the top stories covered by DocWire News this week in the Hematology & Oncology section. This week, a study found that chemotherapy during pregnancy may be safe, a certain type of birth control reduces ovarian cancer risk, and more.
A study published in The Lancet Haematology found that maternal survival was not impacted when pregnant women with Hodgkin lymphoma received antenatal chemotherapy during pregnancy. The researchers noted that this suggests “that antenatal chemotherapy or deferral of treatment until postpartum in selected patients can be considered, with regular obstetric follow-up to safeguard fetal growth.”
A group of researchers from the University of British Columbia has recently developed a new set of exercise guidelines for cancer survivors. This new research recommends specific exercise regimens to address various side effects tethered to cancer treatments and diagnoses, such as fatigue and anxiety. These guidelines were published online in Medicine & Science in Sports & Exercise.
Women who use intrauterine devices for birth control have a reduced risk of ovarian cancer, according to a study published in Obstetrics & Gynecology.
Patients with psoriasis have an increased risk of cancer and cancer-related mortality, according to a study published in JAMA Dermatology.
People who are overweight before the age of 40 incur a higher risk of cancer, according to a study published in the International Journal of Epidemiology.
In case you missed it, more hem/onc headlines are featured below:
- Trastuzumab Deruxtecan vs. Herceptin: How Do These Breast Cancer Drugs Compare?
- Nivolumab Plus Bevacizumab Combo Effective in Relapsed Ovarian Cancer
- Where Cancer Survivors Live Impacts Obesity Risk
- AI Highly Accurate in Upper Gastrointestinal Cancer Detection
- Improving Specialist Referral Times for Patients at Low Risk for Colorectal Cancer